TW200304372A - Compositions for diabetes - Google Patents
Compositions for diabetes Download PDFInfo
- Publication number
- TW200304372A TW200304372A TW092105985A TW92105985A TW200304372A TW 200304372 A TW200304372 A TW 200304372A TW 092105985 A TW092105985 A TW 092105985A TW 92105985 A TW92105985 A TW 92105985A TW 200304372 A TW200304372 A TW 200304372A
- Authority
- TW
- Taiwan
- Prior art keywords
- diabetes
- coenzyme
- composition
- scope
- soup
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 40
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 40
- 210000004369 blood Anatomy 0.000 claims abstract description 33
- 239000008280 blood Substances 0.000 claims abstract description 33
- 230000000694 effects Effects 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 239000005515 coenzyme Substances 0.000 claims description 49
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 235000000346 sugar Nutrition 0.000 claims description 14
- 102000004877 Insulin Human genes 0.000 claims description 9
- 108090001061 Insulin Proteins 0.000 claims description 9
- 229940125396 insulin Drugs 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 235000013376 functional food Nutrition 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 5
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 3
- 229940123208 Biguanide Drugs 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 230000002485 urinary effect Effects 0.000 claims description 3
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000002249 Diabetes Complications Diseases 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 230000005611 electricity Effects 0.000 claims 1
- 230000002414 glycolytic effect Effects 0.000 claims 1
- 235000013548 tempeh Nutrition 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 46
- 239000008103 glucose Substances 0.000 abstract description 46
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 abstract description 6
- 201000001421 hyperglycemia Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 2
- 235000014347 soups Nutrition 0.000 description 37
- 235000013305 food Nutrition 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 230000006872 improvement Effects 0.000 description 9
- 244000269722 Thea sinensis Species 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 235000013616 tea Nutrition 0.000 description 7
- 244000025254 Cannabis sativa Species 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 4
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 235000017803 cinnamon Nutrition 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- -1 fatty acid monoglycerides Chemical class 0.000 description 4
- 108091005995 glycated hemoglobin Proteins 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 244000018436 Coriandrum sativum Species 0.000 description 3
- 235000002787 Coriandrum sativum Nutrition 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 240000005373 Panax quinquefolius Species 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 244000299790 Rheum rhabarbarum Species 0.000 description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000234435 Lilium Species 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 240000005125 Myrtus communis Species 0.000 description 2
- 235000013418 Myrtus communis Nutrition 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 240000008866 Ziziphus nummularia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000019226 kombucha tea Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- SOECUQMRSRVZQQ-UHFFFAOYSA-N ubiquinone-1 Chemical compound COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O SOECUQMRSRVZQQ-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NAYVPMNXHYLSBP-UHFFFAOYSA-N 2,3,4,5,6-pentaethylpyridine Chemical compound CCC1=NC(CC)=C(CC)C(CC)=C1CC NAYVPMNXHYLSBP-UHFFFAOYSA-N 0.000 description 1
- LYBURMLGGDRMDL-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]butanoic acid Chemical compound CCC(C(O)=O)N(CC(O)=O)CCN(CC(O)=O)CC(O)=O LYBURMLGGDRMDL-UHFFFAOYSA-N 0.000 description 1
- DMQQXDPCRUGSQB-UHFFFAOYSA-N 2-[3-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCCN(CC(O)=O)CC(O)=O DMQQXDPCRUGSQB-UHFFFAOYSA-N 0.000 description 1
- JAGQEJXPXPGNJB-UHFFFAOYSA-N 2-[carboxymethyl(hydroxy)amino]acetic acid Chemical compound OC(=O)CN(O)CC(O)=O JAGQEJXPXPGNJB-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000006054 Agastache cana Species 0.000 description 1
- 235000017334 Alcea rosea Nutrition 0.000 description 1
- 240000000530 Alcea rosea Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 235000001270 Allium sibiricum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000017303 Althaea rosea Nutrition 0.000 description 1
- 241000599805 Apium graveolens Secalinum Group Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 241000490494 Arabis Species 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108060006004 Ascorbate peroxidase Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- SRUKAOFCPBFUIE-UHFFFAOYSA-N C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.C(CC)O Chemical compound C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.C(CC)O SRUKAOFCPBFUIE-UHFFFAOYSA-N 0.000 description 1
- XNSPQPOQXWCGKC-UHFFFAOYSA-N C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.[N] Chemical compound C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.[N] XNSPQPOQXWCGKC-UHFFFAOYSA-N 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000825839 Cantinoa mutabilis Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 244000166675 Cymbopogon nardus Species 0.000 description 1
- 235000018791 Cymbopogon nardus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000206389 Helleborus Species 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241000208181 Pelargonium Species 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 235000010674 Prunella vulgaris Nutrition 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 235000013559 Schnittsellerie Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000519999 Stachys Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 102000004385 Sulfurtransferases Human genes 0.000 description 1
- 108090000984 Sulfurtransferases Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 240000000785 Tagetes erecta Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241001530097 Verbascum Species 0.000 description 1
- 235000004031 Viola x wittrockiana Nutrition 0.000 description 1
- 244000047670 Viola x wittrockiana Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- DTQFKZRVARUELC-GEMLJDPKSA-N [S].OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O Chemical compound [S].OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O DTQFKZRVARUELC-GEMLJDPKSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000000183 arugula Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000010227 chenpi Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000009431 guipi Substances 0.000 description 1
- 239000010358 hachimijiogan Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000009419 huanglian-jie-du decoction Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000008876 liujunzi Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000008473 mahuang fuzi xixin Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000020332 matcha tea Nutrition 0.000 description 1
- 239000009799 maxingganshi Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000009728 shiwei Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YHULXGUCQZFROV-UHFFFAOYSA-N sulfane;urea Chemical compound S.NC(N)=O YHULXGUCQZFROV-UHFFFAOYSA-N 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003698 vitamin B derivatives Chemical class 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 235000020334 white tea Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pediatric Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Husbandry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
200304372 玖、發明說明: 【發明所屬之技術領域】 本發明係關於一種含有輔酶Q而成之糖尿病用組成物 【先前技術】 糖尿病為最常見之重大生活習慣病,己知全世界有 100萬人以上患者。再者,血糖值稍偏高之所謂糖尿病潛 在群人數則遠超過上述糖尿病患者人數。因此糖尿病為全 世界性重大疾病。 糖尿病己知有因胰島素分泌不完全所造成之丨型糖尿 病(胰島素依賴性糖尿病)及因對胰島素之感受性減低所造 成之π型糖尿病(胰島素非依賴性糖尿病)。大多數糖尿病 患者為II型糖尿病,此類型糖尿病多因飲食過量等不適 §生活習慣而發病。 糖尿病之問題點在於,因無高血糖所產生之自覺徵狀 ’、而容易變成長期之血糖控制不&,以致引起許多併發症 (視網膜症、腎疾病、動脈硬化等)。例如在日本,成人視 力障礙原因疾病之帛i位為糖尿病性視網模症,而因慢性 腎衰竭以致人工透析原因疾病之f 2位為糖尿病性腎疾病 :由於發生如此嚴重之併發症,故治療糖尿病之首要目的 為嚴袼維持血糖之控制。 對 泌不足 患者, I型糖尿病患者之血糖控制,因其病因為騰島素分 ’故注射騰島素具有絕大效果。但對II型糖尿病 因其對胰島素之感受性減低,故注射胰島素多無法 200304372 展現有效性。對此種11型糖尿病患者之治療,首先選擇 實施飲食控制以限制由飲食攝取過多熱量或促進消耗體内 熱量之運動療法,但長期之飲食控制往往難以繼續而困難 車父多。對於飲食控制與運動療法無顯著進展之患者則試用 糖尿病藥(磺醯尿素劑、縮二胍劑等),但此等藥劑均有很 大的問題。磺醯尿素劑(SU劑)為由1 970年代起使用第2 代藥劑之具有長期使用經驗之藥劑,己知因過度減低血糖 值而易引起低血糖。另外因增強空腹感而易引起脫離飲食 控制,不僅使血糖控制失敗,並常助長肥胖。因為有此種 問題故使用SU劑須要由醫師嚴密控制。另一方面,縮二 脈劑(BG劑)亦為由1 970年代起使用之藥劑,但許多報告 指出,該藥劑在開始使用後不久即會發生乳酸酸中毒此種 副作用。近年雖然對其使用方法與有效性重新評估,但此 藥劑亦須要在醫師嚴格管理下使用。 在此種情況下嘗試開發新的口服糖尿病藥,並有α 一 葡萄糖苷酶抑制劑及胰島素作用增強劑等開發,但因使用 經驗尚少’故是否能成為安全性高之有用藥劑,尚有待今 後之探討。事實上,胰島素作用增強劑托羅葛力他松 (troglitazone)因肝疾之副作用而中止開發。 因此糖尿病患者能安心使用且安全性高之口服藥劑為 幾無狀態’故實際治療糖尿病之核心為飲食控制亦不為過 丄但嚴格進行飲食控制實際上常有其困難。為使飲食控制 谷易進打己有開發各種糖尿病用低熱量食品,但對治療糖 尿病之貢獻僅為-小部分。再者,對因糖尿病所特別引起 200304372 之併發症之治療藥劑亦無,故現狀係藉由嚴密控制血糖值 以兼顧預防併發症。因此期望開發出對糖尿病為安全性高 且有用之藥劑、或即使在飲食控制下仍能安心攝取之有效 食品等。 輔酶Q為廣汎分佈於由細菌至哺乳動物活體中之必須 成分,己知為活體内細胞中之粒腺體電子傳遞系統之構成 成分。輔酶Q除在粒腺體中重複氧化與還原以擔負電子傳 遞系統之傳遞成分外,還原型輔酶Q已知具有抗氧化作用 。在人體以輔酶Q之側鏈具有ίο個重複構造之輔酶q1g為 主成分。 輔酶Q1q之重要特徵可舉其高度安全性。在對大鼠之 慢性毒性試驗,曾有報告指出以1 200mg / kg /日之劑量 每日投藥連續52週亦完全無毒性影響(K.D.Williams以 a/, J· Agric. Food Chem.,47:3756-3763, 1999)。 輔酶Q1Q之氧化型輔酶Q1()在日本廣汎使用為充血性心 哀竭藥’在歐美則廣汎使用為健康食品。雖然在氧化型輔 酶Q1G與糖尿病之關係上,有暗示其效果之報告 (Shlm〇mura,Y•以 臨床與研究,58:1349-1352,1981) ,但實際上使用還原型輔酶I。對糠尿病患者之有效性則 未知還原型輔酶Qi。視為氧化型輔酶q1q之活化型物質, 但因在空氣中容易氧化轉換為氧化型輔酶Qh,故從未使用 為製品。本發明者先前曾發現單獨與氧化型輔酶Qiq比較 時,混合還原型輔酶Qiq之結果可提升輔酶Qh全體之口服 吸收14 (日本專利特開平1〇〜號公報),但對糖尿病 200304372
Qi〇相較於氧化型輔酶Qig是否表現優 等疾病,還原型輔酶 異效果則未明。 【發明内容】 本發明之目的在於對糖尿病患者提供血糖控制優異且 安全性高之口服組成物。 、 本發明者等為解決上述課題而研究結果,發現使 酶Q、尤其還原型麵Q,可獲得對糖尿病有
亦即,本發明係關於含有以下式(i) OH
OH (1) Q做為有效成 (式中n為i〜丨2整數)所表示之還原型輔酶 分之糖尿病用組成物。 又本發明係關於含有上述還原型輔酶Q及以下 〇 ^(2) H3C〇J^^J、(CH2CHC(CH3}CH2) Η
II ο (2) Q做為有效成 (式中η為i〜i2整數)所表示之氧化型輔酶 分之糖尿病用組成物。 200304372 # # ’本發明係關於輔酿 用組成物;同時含有糖/Q為她‘之上述糖尿病 组成物._治療用㈣之上述糖尿病用 、、且成物,糖尿病用治痒 一 ’、 樂Μ為%醯尿素劑、續胺劑、縮 =之二,酶抑制劑、胰島素作用增強劑、或 夷島素之上述糖尿病用組成物。 本發月係、關於含有上述糖尿病用組成物而成之醫藥 品、機能性食品、動物用飼料。 、 再者,本發明係關於使用上述糖尿病用組成物之血糖 控制方法、糖尿病併發症預防方法。 【實施方式】 以下詳述本發明。 辅酶Q係以下式(1) ΟΗ
Η3 H3CC
〇^V^NCH2CHC(CH3)CH2) η Η OH (l) (式中η為1〜12整數),及以下式(2) 0
H3CO^\^>^(CH2CHC(CH3}CH2) η Η
II ο 式(1)為還原型輔酶Q, (式中η為1〜12整數)所表示者。 200304372 式(2)為氧化型輔酶Q。 獲知氧化型輔酿Q及還原型輔醃 定m ^ a 之方法並無特別限 例如可採用以合成、發酵、由天然物萃取等習用己知 得輔酶Q:,以色層法將流出液中之氧化型輔酶Q =還原型_卩成分加以濃縮之方法等。氧化型輔酶 Q可由習用己,方法獲得。欲獲得還原型辅酶㈣,依需 要對上述輔酶Q添加硼氫化鈉、遠― b 奶運一亞硫酸鈉(亞硫酸氫
幻專-般還原劑,依常法將上述_ Q還原為還原型輔
Si Q後進行以色層法之濃縮亦可。又對既有之高純度輔酶 Q使上述還原劑作用之方法’亦可獲得還原型辅酶卩。 使用於本發明之輔酶Q可舉出以式⑴及式⑵所表示 之:鍵之重複單位(式中0為卜12者,其中以側鍵之重 複單位為10之輔酶Q1Q特別適合使用。 本發明之糖尿病用組成物以含有上述還原型輔酶Q為 有效成分而成,或以含有上述還原型輔酶Q及上述氧化型 輔酶Q為有效成分而成。
獲得上該糖尿病用組成物之方法並無特別限定,例如 將以上述方法所得還原型輔酶Q 、或將該還原型輔酶Q與 如以上述方法所得氧化型輔酶Q溶解於異丙醇、丙酮、乙 醚等通常使用之適當溶劑,可得含所需量之上述還原型輔 酶Q之組成物。又上述還原型輔酶Q能以固體狀態直接使 用’或上述還原型輔酶Q與上述氧化型輔酶q以固體狀態 混合。再者,亦可將在上述輔酶Q之製造步驟所得氧化型 輔酶Q與還原型輔酶q之混合物直接使用。又控制上述既 11 200304372 有之高純度辅酶Q之還原反應時間及還原劑之種類或其使 用篁’亦可直接獲得本發明之組成物。 含量,由效果 重量%較好, 於本發明之糖尿病用組成物,其輔酶Q 及價格之觀點,以組成物全量之〇. 〇 〇 1〜2 〇 0.01〜10重量%更好。 還原型輔酶Q之含量,由更為優異效果之觀點,以補 酶Q全量之60重量%以上較好,8〇重量%以上更好。 於本發明之糖尿病用組成物,可再同時含有糖尿病用 治療用藥劑。該糖尿制治療㈣劑可舉例如杨尿素劑 、磺胺劑、縮二胍劑、α -葡萄糖苷酶抑制劑、胰 用增強劑、胰島素等。 —該糖尿制治療㈣狀含量並無特別限定,可因應 醫藥品、機能性食品、動物用飼料等用途而適當決定。 本發明之糖尿病用組成物具有耐糖能力改田善效果及血 糖控制改善效果#,因此於肋糖以發病、 、及糖尿病併發症之預防等方面有效。 ,、 扃 又該糖尿病用組成物可用於血糖 ^ 爾徑制方法、糖尿病併 發症預防方法等。 上述本發明之糖尿病用組成物, 醫薤口地Θ 了使用於如糖尿病用 邊梁阳、糖尿病用機能性食品或食 田Μ』丨你 原枓、糖尿病用動物 用飼枓專。在此所謂機能性食品係指 相口服添加物、特定保 健用食品、健康食品、補助營養食品等醫藥品以外之經由 口服攝取以維持或改善健康為目的之製品。 又該糖尿病用組成物只要是以辅酶U口服為目的或 12 200304372 則可無任何限制 以辅酶Q與藥劑之口服為目的之組成物 而使用。
本發明之糖尿病用組成物當做醫藥品、機能性食口 動物用飼料等使用時,其劑型並無任何限制,如可為於劑 ^可加黏合劑(binder)成為顆粒劑,可將粉末以塗覆=做 塗覆,亦可將粉末劑或顆粒劑及塗覆劑充填於膠囊中成為 膠囊劑。又可添加天然油、油狀高級脂肪酸、高級脂肪酸 單甘油酯、界面活化劑、或此等之混合物等,以油狀直接 填充成軟膠囊劑。此時亦可使用以明膠為主體或其他水溶 性尚分子物質為主體等者。又此種膠囊包含微膠囊。 再者,特別使用於機能性食品等時,亦可將上述輔酶 Q含於習用糖尿病用食品類。
為避免還原型輔酶Q被氧化,該糖尿病用組成物中最 好添加抗氧化劑’⑮因劑型而有時亦可不添加。在此可使 用之抗氧化劑可舉例如檸檬酸、檸檬酸衍生物、維生素C 、維生素c衍生物、茄紅素、維生素A、類胡蘿窗素、維 生素B、維生素B衍生物、類黃酮類、多酚類、谷胱甘肽 、砸^硫代硫酸納、維生素E、維生素E衍生物、超氧化 岐化酶(SGD)、谷胱甘肽過氧化酶、谷胱甘肽硫移轉酶、谷 胱甘肽還原酶、過氧化氫酶、抗壞血酸過氧化酶、及此等 之混合物等。 同樣由防止氧化之觀點可使用螯合劑。該螯合劑可舉 例如乙一胺四乙酸及其鹽、乙二胺二乙酸及其鹽、羥亞胺 基二乙酸及其鹽、M乙基乙二胺四乙酸及其鹽、二乙三胺 13 200304372 五乙酉夂及其鹽、氮川三乙酸及1 赜—私 /、现二乙四胺六乙酸及其 ^ 一羧尹基谷胺酸四鈉鹽、二羥甲其 一 ^ 叛严基甘氨酸、1,3—丙 一胺四乙酸及其鹽、13—二 酺、«艫舻如碰 2~羥丙烷四乙酸及其 息fc糖i納鹽、經乙又二膦酸、氮川三㈣基 (nitrilotris)、賴丁燒三«、及此等之混合物#/ 再者上述柷氧化劑與螯合劑亦可併用。 本㈣之糖尿制組成物中除上述還原型輔酶q外, 將樂劑學及食品衛生學容許之其他原料,以常法適者 添加混合。㈣解及食品衛生學容許之其他原料並^ :限制:/舉例如賦形劑、崩解劑、潤滑劑、黏合劑= 覆劑、著色劑、凝集防止劑、促 從進吸收劑、溶解助劑、安 定化劑、健康食品原料、營養補 呂菁蒱助食品原料、維生素等。 上述賦形劑無特別限制’可舉例如薦糖、乳糖'葡萄 糖、玉米殿粉、甘露糖醇、結 地 ^ 、口日日纖維素、磷酸鈣、硫酸鈣 等。 上述崩解劑無特別限制,可舉例如殺粉、洋菜、檸檬 酸鈣、碳酸鈣、碳酸氫鈉糊护 ^ * L閉糊積、結晶纖維素、羧甲基纖 維素、西黃蓍膠等。 紙 /述潤滑劑無特別限制,可舉例如滑石粉、硬脂酸鎂 、聚乙二醇、二氧化矽、硬化植物油等。 上述黏合劑無特別限制,可舉例如乙基纖維素、甲基 纖維素、經丙甲基纖維素、西黃著膠、蟲膠、明膠、阿; 伯膠、聚乙烯吡咯烷_、繫△锐π ^ w 眾乙烯_、聚丙烯酸、聚曱基 烯酸、山梨糖醇等。 200304372 上述塗覆劑無特別限制’可舉例如阿拉伯膠 (寧㈣、夏枯草、軟蠛、羧基乙_合物 -乳切、㈣鎂、醋酸乙稀樹脂、硬脂酸 丙甲基纖維素等。 風办# ^述著色劑無特別限制,可使用如允許添加於醫藥品 或食品者。 上述凝集防止劑無特別限制,可舉例如硬脂酸、 籾、輕質無水碎酸、含水二氧化碎等。 上述促進吸收劑無特別限制,可舉例如高級醇類、古 級脂肪酸類、甘油脂肪酸酯等界面活性劑。 同 上述助溶劑無特別限制,可舉例如富馬酸 蘋果酸等。 桃拍%、 上述安定化劑無特別限制,可舉例如苯甲酸 鈉、對羥基苯甲酸酯等。 不τ酉夂 “上述健康食品原料無特別限制,可舉例如中藥(例 :有、溫經湯、溫清飲、黃¥建中湯、黃蓮解毒湯、 有、葛根湯、加味歸脾湯、加味逍遙散、甘麥大棗湯κ 、命脾湯、九味檳榔湯、莉芬連勉湯、桂皮加与藥大 只芴、桂皮加与藥湯、桂皮加龍骨牡蠣湯、桂枝湯 人參湯、桂枝获茶丸、啟脾湯、香蘇散、五虎湯、五 牛車腎軋丸、五淋散、柴陷湯、柴胡加龍骨牡蠣湯 ^桂皮乾姜湯、柴胡桂枝湯、柴胡清肝湯、柴朴湯、此^ 湯'酸棗仁湯、滋陰降火湯、四逆散、四君子湯、四= 、炙甘草湯、与藥甘草湯、十全大補湯、十味敗毒湯、 15 200304372 ^ 小柴胡湯、小青龍湯、消風散、辛夷清肺湯、神 秘湯、直决、、窃 . 生1具武所、清上防風湯、消暑益氣湯、清心蓮子飲、 二=嘢、疏經活血湯、大黃甘草湯、大黃牡丹皮湯、大建 中湯、夫jVK » /、月湯、大柴胡湯去大黃、大承氣湯、大防風湯 、治打撲__ir ^ 、調胃承氣湯、釣藤散、腸癰湯、豬苓湯、
::合四物湯、通導散、桃核承氣湯、當歸飲子、當歸 、苟虽知芍藥散、當歸湯、二陳湯、女神散、人參湯 二參養榮湯、排膿散及湯、麥門冬湯、八味地黃丸、半 半U心湯、白虎加人參湯、获荟飲、获茶飲 ^ =厚朴湯、平胃散、防已黃蓍湯、防風通聖散、補中 丸“、麻黃湯、麻黃附子細辛湯、麻杏甘石湯、麻子仁 ☆ 4 a方已π、抑肝散、抑肝散加陳皮半夏、六君子湯、 夕政、龍膽瀉肝湯、苓甘姜呋 ^ ^ 茶 7甘要未辛夏仁濟、六味丸等), 花二广、縫米茶、抹茶、煎茶、培茶、培茶、莱莉 花*才、、烏龍茶、么欠 m ^
草(如意大利序、.Λ香、、、余、花茶、青茶、白茶等),藥 皺葉苴“」、土木香、撖欖、牛至、刺菜薊、甘菊、 、、貶刑芥、葛樓子或藏茴香、嚏根草
::或:嵩、錦㈣用小地榆、綿杉菊、肉:L 膽4精、西洋菩提樹、香天竺莫、金絲桃、息龍 香蔥、、:令:里香、艾菊、細葉芹或還亮草、肖夷蔥或細 、亞:―、、棗、九層塔或羅勒、忍冬、喜蘇或牛膝草 、香:草:香、毛地黃、黑蜀葵、萬壽菊或孔雀草、水蘇 、:璃ΤΓ草、佛手柑、大麻葉澤蘭、芸香、金盒花 肌璃羞、白野苦汁薄荷、番櫻桃或桃金孃、毛蕊花、香 16 200304372 化薄荷、薄荷、歐蓍草、熏衣草 、蜜蜂花、玫瑰、迷迭香、紫花香茅、馬鞭草 一“ %化南芥或芝麻菜、野箪葚、 二色堇、勿忘草等),蜂膠,銀杏 取物等。 月卓汁或该等之萃 :、:屬離子類、*白質類、糖類、脂肪酸類、酵母;: 物、心菜萃取物、魚肉萃取物、果實、果實萃取物等 上述維生素無特別限制,可舉例如維生素a類 素B類、維生素C、維生素。類、維生素e類等。 製作本發明之含還原型輔酶Q之糖尿剌組成物時, 型輔酶Q之含量、劑型、保存方法及保存形能,可 =藥品二建康食品、食品、動物用醫藥品、動物用飼 枓4用途而適當決定。 以下用實施例更詳細說明本發明,但本發明不受此等 實施例之限制。 [實施例1]對Π型糖尿病實驗大鼠之效果 ▲使用II型糖尿病實驗大鼠之GK大鼠(5週齡、雄性) -平估還原型輔酶I。及氧化型輔酶Q”之耐糖能力改善效 果。還原型輔酶Q10及氧化型輔酶Qi〇各以〇1重量^粉 狀飼料混合,讓實驗動物自由攝取。但為防止混合飼料中 之還原型辅酶Q〗。因氧化而減少,故以2日i次之頻率全 量更換新飼料。對照群攝取不含輔酶Qi。之粉狀飼料。在 開,攝取混合飼料,經4週後及6週後實施耐糖能力試驗( 、、、4又n~4)。耐糖能力試驗時,將50%葡萄糖溶液以 17 200304372 / kg技予量做經口投予,測定投予前及投予後30分 里6G刀鐘、90分鐘、120分鐘之血糖值。血糖值以由尾
靜脈採血’用簡易型血糖測定器來定量。其 圖2表示。 W 凡圖1為投予4週後之耐糖能力試驗結果。氧化型辅酶 ^投予群與對照群比較時,可顯著抑制糖負擔3q分鐘後 之血糖值上升,表現耐糖能力改善效果。又於還原型輔酶 Q1〇投予群,在糖負擔30分鐘後開始之所有測定時間,其 血糖值較氧化型輔酶qig大為減低,表現更優異之耐糖能 力改善效果。 圖2進一步顯示投予6週後之試驗結果。氧化型輔酶 投予群之耐糖能力較上述4週後之結果更見改善,與投 予4週後之氧化型輔酗q丨q比較時更可抑制糖負擔後之血 糖值上升。又於還原型輔酶Qiq投予群,在所有測定時間 更可有效地抑制血糖值上升,在所有測定點之血糖值均為 200mg / dl以下,與投予4週後比較時更加改善耐糖能力 〇 由上獲知投予氧化型輔酶Q1Q可改善GK大鼠耐糖能力 。又由試驗結果闡明投予還原型輔酶Q1Q時與投予氧化型 輔Q1 〇比較更加改善G K大鼠耐糖能力。玩味者為,在氧 化型輔酶1 〇投予群,其耐糖能力改善模式在投予4週後 及投予6週後相同,雖可抑制糖負擔30分鐘後之血糖值 上升,但血糖值持續上升1小時後乃成為大致橫向曲線, 與對照群無大差異。但還原型輔酶Q1Q投予群之耐糖能力 18 200304372 改善模式,無論投予4週後及投予6週後㈣ 鐘時為高峰·值,盆後 %利刀 -後酼時間之經過而血糖值下降。而經過 回值30分鐘後之血糖值顯著低於對照群,明顯可確認 耐糖能力之改善。此種還原型輔酶Q1〇之财糖能力改盖模 式與乳化型辅目Ql。之改善模式不同,實令人驚奇。本發 明者等在先前之研究曾閣明氧化型輔目Qi。與還原型輔酶 1。之經口吸收性有差異(日本專利特開平i卜⑽咖號公 報)〃。但本次試驗結果所得對GK大鼠耐糖能力改善效果, 其虱化型與還原型之效果模式不同。此種結果不能單以吸 收性之差解釋,因此被認為使用還原型輔酶之結果在 活體内可能獲得與氧化型辅酶Qiq不同之效果。 。 [實施例2 ]對血中糖化血紅蛋白量之影響 與實施例1相同方法,測定飼養12週GK大鼠之血中 糖化血紅蛋白(血紅蛋白Alc)含量。其結果如表〗所示, 還原型辅酶q1g投予群顯著較對照群之血紅蛋白Alc值減 少達其78% ,而在氧化型輔酶Qiq投予群雖減至其92%但未 達顯著減少,且較還原型輔酶Qiq投予群之減少值差。糖 化血紅蛋白為血糖控制之重要指標而應用於臨床之參數。 在還原型辅酶q1q投予群獲得顯著減少值,表示因投予本 物質而改善GK大鼠之血糖控制。在氧化型輔酶Qiq投予群 則僅止於少許之減少,其改善效果低於還原型輔酶Q"投 予群。此被認為是實施例1所示耐糖能力改善不良反映在 糖化血紅蛋白含量上。 200304372 表1 W~ 白 Ale 值
5.33 ±0.48 (100) 4.17+0.15 (78**) 4.93 ±0.42 (92) 還原型輔酶Q1()投予群 投予群 相較於Student t-test對照群顯現有效差 **Ρ<0·01 產業上之可利用性^ 依據本發明’可對糖尿病患者及其潛在群之耐糖能力 異常者,提供-種在維持良好血糖控制上有益之組成物。 又以輔酶Q為主要成分之本發明之糖尿病用組成物,因其 安全性高,故可長期服用,為有用性高之組成物。再者, 依據本發明’可提供一種不限於人類而對寵物等之糖尿病 亦有用之組成物。 【圖式簡單說明】 圖1表示攝取含輔酶qiq飼料4週之gk大鼠耐糖能力 之座標圖。縱座標軸以mg / d 1表示血糖值,橫座標軸以 分鐘表示負擔葡萄糖後經過之時間。所標繪為4隻之平均 值土標準偏差。記號代表•:對照群、〇:還原型輔酶Q10 (含2%氧化型辅酶qi())群、□:氧化型辅酶^◦群。*、* 木各代表顯者水準未滿5 %及未滿1 %時,相對於對照組有明 顯的差異(Dunnet檢測)。 圖2表示餵食含輔酶Q1G飼料6週之GK大鼠耐糖能力 之座標圖。縱座標軸以mg / d 1表示血糖值,橫座標軸以 分鐘表示負擔葡萄糖後經過之時間。所標繪為4隻之平均 200304372 值土標準偏差。記號代表# :對照群、〇:還原型輔酶Q1〇 (含2%氧化型輔酶Q1Q)群、□:氧化型輔酶Q1Q群。*、* *各代表顯著水準未滿5%及未滿1 %時,相對於對照組有明 顯的差異(Dunnet檢測)。
21
Claims (1)
- 200304372 拾、申請專利範圍: 1 · 一種糖尿病用組成物,係含有以下述式(1) OHOH (1)(式中,n為1〜12整數)所表示之還原型輔酶q做為有效 成分。 … 2 · —種糖尿病用組成物,係含有還原型辅酶Q及以下 述式(2)H3CO^\^>^(CH2CHC(CH3)CH2) n H Ο^分中。,η為1〜12整數)所表示之氧化型輔酶Q做為有 3·如申請專利範圍第1項或第2項之糖尿病用电成 ,其中,輔酶Q為輔酶Qi〇。 、、且成 4·如申請專利範圍第卜3項中 物,苴中,孫、隹止a 員之糖尿病用組 進一步含有糖尿病用治療用藥劑。 5·如申請專利範圍第4項之糖尿病 糖展病H㈣藥劑為料尿 ㈤’其中 別’胺劑、縮二胍#1 22 200304372 α —葡萄糖苷酶抑制劑、牍 腾島素作用增強劑或胰島素。 6·—種糖尿病用醫蘸 用通梁口口,其特徵在於,係含有申請專 利範圍第1〜5項中任一項之撼尸产 月寻 貝之糖尿病用組成物。 7·一種糖尿病用機能性食品,其特徵在於,係含有申 請專利範圍第1〜5項中任一頂夕挑户 項之糖尿病用組成物。 8· -種糖尿病用動物用飼料,其特徵在^,係含 請專利範圍第卜5項中任—項之糖尿病用組成物。 9 · 一種血糖控制方法,豆牯,、特徵在於,係使用申請專利 範圍第1〜5項中任一項之糖尿病用組成物。 方法,其特徵在於,係使 項之糖尿病用組成物來預 1 〇 · —種糖尿病併發症預防 用申請專利範圍第1〜5項中任一 防糖尿病併發症。 拾壹、囷式: 如次頁23
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002077909 | 2002-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200304372A true TW200304372A (en) | 2003-10-01 |
Family
ID=28035546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092105985A TW200304372A (en) | 2002-03-20 | 2003-03-19 | Compositions for diabetes |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050113459A1 (zh) |
EP (1) | EP1493437A4 (zh) |
JP (1) | JP4653400B2 (zh) |
KR (1) | KR100591045B1 (zh) |
CN (1) | CN100381119C (zh) |
AU (1) | AU2003221136B2 (zh) |
CA (1) | CA2476906A1 (zh) |
TW (1) | TW200304372A (zh) |
WO (1) | WO2003077895A1 (zh) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2578347A1 (en) * | 2004-08-30 | 2006-03-09 | Kaneka Corporation | Mitochondria activators |
ES2563929T3 (es) * | 2004-12-24 | 2016-03-16 | Kaneka Corporation | Preparación sólida que comprende coenzima Q10 reducida y proceso para la producción de la misma |
JP2007028997A (ja) * | 2005-07-27 | 2007-02-08 | Kanebo Seiyaku Kk | 生薬エキス配合流動食及びその使用 |
JPWO2007034852A1 (ja) * | 2005-09-22 | 2009-03-26 | 株式会社カネカ | 延命用組成物及び寿命を延長する方法 |
KR20080097437A (ko) * | 2006-01-25 | 2008-11-05 | 가부시키가이샤 가네카 | 혈압 정상화 조성물 |
US20080075792A1 (en) * | 2006-09-21 | 2008-03-27 | Naturalendo Tech Co., Ltd. | Method for inhibiting the activity of DPP-IV and lowering blood glucose level |
KR100899889B1 (ko) * | 2007-07-15 | 2009-06-01 | 전현철 | 레몬 및 레몬밤을 함유하는 침출차와 액상추출차의 제조방법 및 그로부터 제조한 침출차와 액상추출차 |
KR100899890B1 (ko) * | 2007-07-16 | 2009-06-01 | 전현철 | 레몬 및 레몬버베나를 함유하는 침출차와 액상추출차의 제조방법 및 그로부터 제조한 침출차와 액상추출차 |
US20090098228A1 (en) * | 2007-10-10 | 2009-04-16 | Tsumura & Co. | Agent and method for improvement of impairment of learning and memory |
JP6081195B2 (ja) * | 2009-05-11 | 2017-02-15 | バーグ エルエルシー | エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する腫瘍性障害の診断のための方法 |
EP2544663B1 (en) | 2010-03-12 | 2018-01-03 | Berg LLC | Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
CN103608323B (zh) | 2011-04-04 | 2016-08-17 | 博格有限责任公司 | 治疗中枢神经系统肿瘤的方法 |
PE20180414A1 (es) | 2011-06-17 | 2018-03-01 | Berg Llc | Composiciones farmaceuticas inhalables |
AU2013290463B2 (en) * | 2012-07-16 | 2016-08-11 | Clemson University Research Foundation | Novel food and feed antioxidants and preservatives based on antioxidant enzymes extracted from animal blood |
US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
WO2014138922A1 (en) * | 2013-03-15 | 2014-09-18 | Indanio Bioscience Inc. | Uses for idebenone and related benzoouinones in ppar-related diseases and conditions |
US10933032B2 (en) | 2013-04-08 | 2021-03-02 | Berg Llc | Methods for the treatment of cancer using coenzyme Q10 combination therapies |
IL276423B2 (en) | 2013-09-04 | 2024-05-01 | Berg Llc | Pharmaceutical preparations containing coenzyme Q10 for use in cancer treatment |
US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
AU2015339576B2 (en) | 2014-10-27 | 2020-02-06 | Glytec, Llc | Subcutaneous outpatient management |
US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
WO2017031440A1 (en) | 2015-08-20 | 2017-02-23 | Aseko, Inc. | Diabetes management therapy advisor |
CN111938042A (zh) * | 2020-08-26 | 2020-11-17 | 珠海海龙生物科技有限公司 | 一种提高大口黑鲈糖耐受性的配合饲料及其制备方法和应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4910665B1 (zh) * | 1969-07-24 | 1974-03-12 | ||
US3849344A (en) * | 1972-03-31 | 1974-11-19 | Carborundum Co | Solid diffusion sources containing phosphorus and silicon |
JPS5489036A (en) * | 1977-12-27 | 1979-07-14 | Eisai Co Ltd | Remedy and preventive for hypersensitivity to light |
US4959212A (en) * | 1988-06-22 | 1990-09-25 | Alexandra Stancesco | Oxidizing-energizing composition and method for the treatment of diabetes |
JPH02249492A (ja) * | 1989-03-20 | 1990-10-05 | Lion Corp | ユビキノン9の製造方法 |
DK0643775T3 (da) * | 1992-05-28 | 2004-09-06 | Ct For Molecular Biology And M | Quinonderivater til forbedring af cellebioenergi |
IT1284873B1 (it) * | 1996-07-26 | 1998-05-22 | Idi Farmaceutici Spa | Derivati stabili di ubichinolo procedimenti per la loro produzione e loro impiego farmaceutico |
JP3889481B2 (ja) * | 1996-08-16 | 2007-03-07 | 株式会社カネカ | 医薬組成物 |
ES2159938T3 (es) * | 1997-02-11 | 2001-10-16 | Mse Pharmazeutika Gmbh | Preparados transdermicos, orales e intravenosos de 2,3-dimetoxi-5-metil-6-decaprenil-1,4-benzoquinona. |
IT1291113B1 (it) * | 1997-03-20 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Composizione nutritiva terapeutica per soggetti affetti da diabete mellito |
JP3926888B2 (ja) * | 1997-05-27 | 2007-06-06 | 株式会社カネカ | コレステロール低下剤 |
US8753675B1 (en) * | 2000-01-20 | 2014-06-17 | Raj K. Chopra | Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications |
US6441050B1 (en) * | 2000-08-29 | 2002-08-27 | Raj K. Chopra | Palatable oral coenzyme Q liquid |
JP3742602B2 (ja) * | 2001-05-09 | 2006-02-08 | 株式会社カネカ | 還元型補酵素qの安定な溶液 |
EP1388340B1 (en) * | 2001-05-10 | 2010-09-08 | Kaneka Corporation | Compositions for transmucosal administration containing coenzyme q as the active ingredient |
JP2003026567A (ja) * | 2001-05-10 | 2003-01-29 | Kanegafuchi Chem Ind Co Ltd | 補酵素qを有効成分とする粘膜投与用組成物 |
US6506915B1 (en) * | 2001-06-14 | 2003-01-14 | Daniel David West | Synthesis of coenzyme Q10 ubiquinone |
JP3822479B2 (ja) * | 2001-10-10 | 2006-09-20 | 株式会社カネカ | 還元型補酵素q水溶液の安定化組成 |
TWI329513B (en) * | 2001-10-12 | 2010-09-01 | Kaneka Corp | Use of reduced coenzyme q for lessening oxidative stress |
JP2003135022A (ja) * | 2001-10-31 | 2003-05-13 | Crescendo Corporation | コエンザイムq10 |
-
2003
- 2003-03-19 TW TW092105985A patent/TW200304372A/zh unknown
- 2003-03-20 US US10/505,523 patent/US20050113459A1/en not_active Abandoned
- 2003-03-20 EP EP03712784A patent/EP1493437A4/en not_active Withdrawn
- 2003-03-20 AU AU2003221136A patent/AU2003221136B2/en not_active Ceased
- 2003-03-20 CA CA002476906A patent/CA2476906A1/en not_active Abandoned
- 2003-03-20 KR KR1020047013560A patent/KR100591045B1/ko active IP Right Grant
- 2003-03-20 JP JP2003575948A patent/JP4653400B2/ja not_active Expired - Fee Related
- 2003-03-20 WO PCT/JP2003/003389 patent/WO2003077895A1/ja active IP Right Grant
- 2003-03-20 CN CNB038047926A patent/CN100381119C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
KR100591045B1 (ko) | 2006-06-19 |
AU2003221136A2 (en) | 2003-09-29 |
CN100381119C (zh) | 2008-04-16 |
EP1493437A1 (en) | 2005-01-05 |
CA2476906A1 (en) | 2003-09-25 |
US20050113459A1 (en) | 2005-05-26 |
AU2003221136A1 (en) | 2003-09-29 |
WO2003077895A1 (fr) | 2003-09-25 |
AU2003221136B2 (en) | 2008-05-22 |
KR20040091082A (ko) | 2004-10-27 |
JPWO2003077895A1 (ja) | 2005-07-14 |
CN1691939A (zh) | 2005-11-02 |
JP4653400B2 (ja) | 2011-03-16 |
EP1493437A4 (en) | 2010-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200304372A (en) | Compositions for diabetes | |
KR100645385B1 (ko) | 비만 억제용 조성물 | |
AU2002364213B2 (en) | Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors | |
US20180104299A1 (en) | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity | |
JP2007536250A (ja) | 骨格筋におけるクレアチンの取り込みを増大するための栄養組成物 | |
WO2008034316A1 (fr) | Préparation de composés capable de reduction rapide de stress oxidatif et son procédé de préparation | |
JP2011522844A (ja) | 血糖レベルを低下させる組成物及びその用途 | |
US20050008712A1 (en) | Compositions incorporating high-caffeine green tea extract and related methods for promoting healthy body weight | |
KR101923603B1 (ko) | 녹차 복합 추출물을 유효성분으로 포함하는 항비만 조성물 | |
KR20110105627A (ko) | 누에 체액을 함유하는 항비만 조성물 | |
CN114588216B (zh) | 一种具有降血脂功效的药物组合物及其制备方法和其应用 | |
JP2010030950A (ja) | メタボリックシンドローム予防・治療剤ならびに機能性食品 | |
JP4355967B2 (ja) | 医薬組成物 | |
TW200803828A (en) | Cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent | |
KR100595459B1 (ko) | 비만 억제용 조성물 | |
US20180325915A1 (en) | Chlorophyll composition | |
JP2009062348A (ja) | ケナフ類(ケナフ、ローゼル)の種子成分による血糖値低下作用及び血糖値上昇抑制作用 | |
JP2005289984A (ja) | ハイショウソウを含有する高脂血症改善剤 | |
JP6621558B2 (ja) | 夜間頻尿の予防又は改善剤 | |
KR101695299B1 (ko) | 필발 추출물, 이소플라본을 함유하는 대두 추출물 및 l-카르니틴을 함유하는 비만 또는 고지혈증 예방용 또는 개선용 조성물 | |
JP5452042B2 (ja) | 医薬組成物 | |
EP2958627A1 (en) | Composition for the treatment of metabolic disorders | |
JP2008199973A (ja) | 機能性食品 | |
JP2011246434A (ja) | フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、tg低下剤、糞中脂肪排泄促進剤 | |
JP2005336143A (ja) | 体脂肪合成抑制剤 |